Whitley Aamodt

1 month ago | movementdisorders.onlinelibrary.wiley.com | Whitley Aamodt |David Coughlin |Lisa Solomon |Lynn Eickholt

Introduction At present, there are no disease-modifying therapies for Parkinson's disease (PD) and related disorders (PDRD) and mortality rates are rising,1 making end-of-life (EoL) care an important clinical concern. Data from general adult populations suggest that sex and racial/ethnic disparities exist at EoL.

May 2, 2024 | nature.com | Rachel Paul |Eliza Brody |Justin James |Meredith A Spindler |Whitley Aamodt |Daniel Weintraub | +5 more

AbstractObservational studies in Parkinson’s disease (PD) deeply characterize relatively small numbers of participants. The Molecular Integration in Neurological Diagnosis Initiative seeks to characterize molecular and clinical features of every PD patient at the University of Pennsylvania (UPenn). The objectives of this study are to determine the feasibility of genetic characterization in PD and assess clinical features by sex and GBA1/LRRK2 status on a clinic-wide scale.